The growth rate of a variety exceeds 200%! Enter medical insurance + new product is approved, DPP-4 drug is accelerated

In the first half of this year, a number of imported new drugs came out one after another, among which, DPP-4 inhibitor imported compound hypoglycemic drugs added two new products, namely: gligliptin metformin tablets (2017 / 3 / 22) of bringlingham and gliptin metformin sustained-release tablets (2017 / 5 / 18) of AstraZeneca The approval of the imported compound DPP-4 inhibitor will promote the reshuffle of the domestic market At present, 9 DPP-4 inhibitors have been listed in China Among them, there are 5 single prescriptions: cigliptin tablets (jienuwei), saggliptin tablets (anlize), viggliptin tablets (jiaweile), liggliptin tablets (otanning), and aggliptin tablets (nisina); 4 compound prescriptions: They are cigliptin metformin tablets (jienoda), wiggliptin metformin tablets (yiherui), liggliptin metformin tablets (obinnin) and saggliptin metformin sustained-release tablets (anliger) All of the above-mentioned nine products are imported products of multinational enterprises, and no domestic enterprises have entered the market (click the picture to enlarge) DPP-4 inhibitors have entered the world's best-selling drug diabetes has become one of the most serious public health problems in the world According to the data released by the International Diabetes alliance in 2015, the number of adult diabetes patients in the world has reached 415 million China's diabetes patients rank first in the world, with about 110 million patients There is a large number of diabetes consumers in China, and they are gradually showing a trend of youth In recent years, with the emergence of new hypoglycemic drugs, the market of diabetes drugs has shown a rapid growth trend At present, it ranks the second in the global drug sales after tumor drugs According to the statistics of top 50 drugs sold in 2016, the sales volume of the top 50 products is up to US $210 billion, and the top 50 products with a threshold of more than US $2.1 billion Among them, there are 7 diabetes products in the top 50, which are insulin glargine, sitagliptin, lilaluptide, insulin aspart, insulin lysine, insulin Dieter and cigliptin / metformin The total sales of these 7 products reached 23.39 billion US dollars Among them, DPP-4 inhibitors have two products in the top 50, with sales of US $3.908 billion, ranking 20th; sales of US $2.201 billion, ranking 48th; DPP-4 inhibitors have occupied a place in the global best-selling drugs At present, the main global diabetes drugs are: insulin, DPP-4 inhibitors, GLP-1 receptor agonists, sglt-2 inhibitors, traditional oral hypoglycemic drugs The global diabetes drug market is mainly monopolized by pharmaceutical giants such as MSD, Novo Nordisk, Sanofi and Lilly, with a high market concentration The main products are: mosadong's sigletin, sigletin / Metformin; Novo Nordisk's lilalutide, aspart insulin, Dieter insulin; Sanofi's insulin glargine; Lilly's insulin lypro According to the statistics of global drug data, in 2016, the main products of DPP-4 inhibitors in the world were: cisgliptin of mosadon, compound cisgliptin metformin, vidaleptin of Novartis, saggliptin of Bristol Myers Squibb, compound saggliptin metformin and liggliptin of Lilly Among them, the most outstanding products are cigliptin and compound cigliptin metformin In 2011, the sales of these two products have exceeded US $5 billion, and in 2012-2016, they have exceeded US $6 billion for five consecutive years, ranking the top in the whole DPP-4 inhibitor hypoglycemic market Sitagliptin is a new generation of DPP-4 inhibitor, which was developed by MSD and approved by FDA in 2006 Cigliptin has opened a milestone of a new generation of oral hypoglycemic drugs The drug and its compound preparations have been approved for marketing in nearly 100 countries around the world These two products of mosadon have become the best-selling products in the field of DPP-4 inhibitors From the global sales trend of cigliptin and its compound preparations in 2008-2016, DPP-4 inhibitors maintained a rapid growth in 2008-2012, and the market was relatively stable in 2013-2016 The compound growth rate in 2008-2013 is 35.1%, 34.7% in 2010, 53.8% in 2011, 14.9% in 2012, and only 2.4% in 2013 The market began to slow down in 2013 and slightly decreased in 2016 compared with the same period In 2016, the sales volume of cigliptin was US $3.91 billion, and that of compound cigliptin metformin was US $2.20 billion These two products accounted for more than 65.8% of the global market share of DPP-4 inhibitors Their rapid growth in recent years has driven the overall global diabetes market growth to varying degrees DPP-4 inhibitor, as a new drug for diabetes, is widely used in the treatment of type 2 diabetes With the advantages of good tolerance and safety, low incidence of hypoglycemia and oral use, this kind of products are gradually fully recognized in the clinical guidelines at home and abroad, and the treatment status is constantly improved, and gradually become one of the main forces in the hypoglycemic drug market According to the data statistics of domestic sample hospitals, the sales volume of DPP-4 inhibitors in sample hospitals in 2016 was 170 million yuan Among them, the sales volume of sigletin is 61.61 million yuan, the sales volume of sagletin is 45.98 million yuan, the sales volume of vigletin is 27.98 million yuan, the sales volume of ligletin is 11.49 million yuan, the sales volume of agletin is 4.38 million yuan, the sales volume of sigletin / metformin is 13.55 million yuan, and the sales volume of metformin / wigletin is 350000 yuan The growth rates of the top three products, sigletin, sagletin and vigletin, were 20.9%, 19.8% and 16.6% respectively It is worth noting that the growth rate of cigliptin / metformin is 214.6% over the same period Siggliptin and saggliptin accounted for a large share of DPP-4 inhibitor market, and other products also maintained a higher growth rate compared with the same period In 2016, there were 7 manufacturers involved in DPP-4 inhibitors, all of which were foreign-funded enterprises Among them, simgliptin "zenove" of mosadong accounted for 37.3%, sanggliptin "Ariza" of Bristol Myers Squibb accounted for 28.0%, viggliptin "gavel" of Novartis accounted for 16.9%, and the top three products sold accounted for 82.0% of the market, The other four products, cigliptin / metformin, liggliptin, agliptin and metformin wiggliptin, account for 18.0% of the market share In the past three years, three imported products, sigletin, sagletin and vigletin, have achieved outstanding performance in the domestic market At present, the domestic DPP-4 inhibitor market is still in the introduction period, with rapid growth On March 21 of this year, the Ministry of human resources and social security released the 2017 version of the national directory of drugs for basic medical insurance, work injury insurance and maternity insurance, which attracted great attention Five products of DPP-4 inhibitor have entered the new version of the medical insurance catalog, namely, cigliptin, agliptin, liggliptin, saggliptin, and wiggliptin, with the medical insurance category of class B and limited to second-line drugs At present, the incidence rate of diabetes is high in China, and the market for diabetes drugs is huge The five new DPP-4 inhibitors diabetes oral drugs in the medical insurance catalog are all exclusive varieties The market has been occupied by foreign-funded enterprises, and there is a large space for improvement in the future Referring to the experience that the products will continue to increase after entering the medical insurance over the years, DPP-4 inhibitors will enter the national medical insurance catalog, which will soon promote the acceleration of the drug market In the future, it will provide more choices for clinicians and benefit more patients with type 2 diabetes With the continuous increase of new diabetes drugs in China, it will accelerate the reshuffle of the market pattern of diabetes treatment It is worth noting that in April 2016, the FDA issued new safety warnings for two DPP-4 inhibitors, sagletin and agliptin The FDA warns that oral antidiabetics containing sagletin and agliptin may increase the risk of heart failure in patients with type 2 diabetes, particularly those with a history of heart and kidney disease Summary: the diabetes market has become an indisputable place in the global drug market, and domestic enterprises continue to set off a boom in the research and development of diabetes drugs With the advancement of clinical application, DPP-4 inhibitors have become a hot category for many enterprises Up to now, nearly 100 domestic enterprises have applied for the registration of DPP-4 inhibitors DPP-4 inhibitors, a new oral hypoglycemic drug, are quietly rising in the market Although the market advantage of DPP-4 inhibitors is very obvious, it still needs to be tempered in the market to become the mainstream product in the diabetes market.